| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/MYC.12318 |
| P8608 | Fatcat ID | release_l2r24siltfhktgpatygpsmvyom |
| P698 | PubMed publication ID | 25808822 |
| P5875 | ResearchGate publication ID | 274091822 |
| P50 | author | Thomas J Walsh | Q108430075 |
| Tsiporah Shore | Q57542116 | ||
| P2093 | author name string | Michael J Satlin | |
| Samantha E Jacobs | |||
| Audrey N Schuetz | |||
| Rosemary Soave | |||
| Dora E Corzo-León | |||
| P2860 | cites work | Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008) | Q58814209 |
| β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3) | Q26825753 | ||
| Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature | Q28243864 | ||
| Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation | Q28293483 | ||
| Taxonomy and antifungal susceptibility of clinically important Rasamsonia species. | Q30573842 | ||
| Factors associated with mortality in transplant patients with invasive aspergillosis | Q33867013 | ||
| Breakthrough invasive candidiasis in patients on micafungin | Q33963538 | ||
| Geosmithia argillacea: an emerging pathogen in patients with cystic fibrosis. | Q33963545 | ||
| Human rhinoviruses | Q34321393 | ||
| Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation | Q34368144 | ||
| Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation | Q34450423 | ||
| Breakthrough Hormographiella aspergillata infections arising in neutropenic patients treated empirically with caspofungin | Q34487440 | ||
| Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease | Q34574325 | ||
| Geosmithia argillacea: an emerging cause of invasive mycosis in human chronic granulomatous disease. | Q34626970 | ||
| The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. | Q35193749 | ||
| Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France | Q35363662 | ||
| Infections due to emerging and uncommon medically important fungal pathogens | Q35641420 | ||
| Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. | Q35848794 | ||
| Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality | Q36715387 | ||
| Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ | Q37164067 | ||
| Host defenses against zygomycetes | Q37976050 | ||
| Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia | Q40524745 | ||
| Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades | Q40627835 | ||
| Fatal Trichosporon fungemia in patients with hematologic malignancies | Q43199229 | ||
| Trichosporon species infection in bone marrow transplanted patients. | Q43597716 | ||
| Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. | Q44059632 | ||
| Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. | Q44582257 | ||
| Clinical significance of non-Candida fungal blood isolation in patients undergoing high-risk allogeneic hematopoietic stem cell transplantation (1993-2001). | Q44908393 | ||
| Successful treatment of Trichosporon asahii infection with voriconazole after bone marrow transplant | Q45289648 | ||
| Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. | Q45938423 | ||
| Hormographiella aspergillata: an emerging mould in acute leukaemia patients? | Q50784949 | ||
| A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies. | Q51168535 | ||
| Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. | Q51184875 | ||
| P433 | issue | 6 | |
| P921 | main subject | emerging pathogen | Q108429945 |
| invasive fungal infections | Q55022218 | ||
| P304 | page(s) | 325-336 | |
| P577 | publication date | 2015-03-24 | |
| P1433 | published in | Mycoses | Q1956531 |
| P1476 | title | Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens | |
| P478 | volume | 58 |
| Q28080147 | Antifungal Therapy in Hematopoietic Stem Cell Transplant Recipients |
| Q38960267 | Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis |
| Q89689853 | Clinical evaluation of an in-house panfungal real-time PCR assay for the detection of fungal pathogens |
| Q34546811 | Clinical hepatotoxicity associated with antifungal agents |
| Q92341814 | Clinical-scale production of Aspergillus-specific T cells for the treatment of invasive aspergillosis in the immunocompromised host |
| Q36821646 | Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial |
| Q58761662 | Cost-effectiveness analysis of voriconazole, fluconazole, and amphotericin B for invasive fungal infections following allogeneic hematopoietic stem cell transplantation in Mexico |
| Q90674807 | Development and Applications of Prognostic Risk Models in the Management of Invasive Mold Disease |
| Q38847486 | Disseminated Hormographiella aspergillata infection with involvement of the lung, brain, and small intestine following allogeneic hematopoietic stem cell transplantation: case report and literature review |
| Q40562962 | Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. |
| Q89068714 | Emergence of Azole-Resistant Aspergillus fumigatus from Immunocompromised Hosts in India |
| Q64948530 | Epidemiology and Clinical Features of Invasive Fungal Infection in a US Health Care Network. |
| Q40695503 | Filamentous Fungi in Respiratory Infections. What Lies Beyond Aspergillosis and Mucormycosis? |
| Q37500445 | First case of Arthrographis kalrae fungemia in a patient with cystic fibrosis |
| Q87653249 | GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study |
| Q64982266 | Hepatotoxicity Due to Azole Antimycotic Agents in a HLA B*35:02-Positive Patient. |
| Q39035934 | Hyperglycemia as a possible risk factor for mold infections-the potential preventative role of intensified glucose control in allogeneic hematopoietic stem cell transplantation |
| Q37509216 | Immunotherapy for opportunistic infections: Current status and future perspectives |
| Q36104417 | In Vitro Activity of Isavuconazole against Rasamsonia Species |
| Q33641898 | Infections in Hematopoietic Cell Transplant Recipients: Results From the Organ Transplant Infection Project, a Multicenter, Prospective, Cohort Study |
| Q90600864 | Invasive fungal infections in high-risk patients: report from TIMM-8 2017 |
| Q28067726 | Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations |
| Q37363443 | Long-Term Rasamsonia argillacea Complex Species Colonization Revealed by PCR Amplification of Repetitive DNA Sequences in Cystic Fibrosis Patients |
| Q41987095 | Performance of Targeted Fungal Sequencing for Culture-Independent Diagnosis of Invasive Fungal Disease |
| Q46263165 | Proven Invasive Pulmonary Aspergillosis in Stem Cell Transplant Recipient Due to Aspergillus sublatus, a Cryptic Species of A. nidulans. |
| Q39093853 | Pseudozyma and other non-Candida opportunistic yeast bloodstream infections in a large stem cell transplant center |
| Q98156927 | Rapidly expanded partially HLA DRB1-matched fungus-specific T cells mediate in vitro and in vivo antifungal activity |
| Q40205895 | Risk factors and clinical outcomes of breakthrough yeast bloodstream infections in patients with hematological malignancies in the era of newer antifungal agents. |
| Q40515140 | Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field |
| Q38978705 | Serious fungal infections in Canada. |
| Q40454886 | The Changing Epidemiology of Invasive Fungal Infections. |
| Q64267802 | The mitochondrial thiamine pyrophosphate transporter TptA promotes adaptation to low iron conditions and virulence in fungal pathogen Aspergillus fumigatus |
Search more.